Infection, human immunodeficiency virus Trials in Austin, United States
Conditions / Infection, human immunodeficiency virus / Austin, United States
Research into Infection, human immunodeficiency virus spans multiple therapeutic approaches and trial phases.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01068925 | Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers | COMPLETED | PHASE1 |
| NCT02120352 | A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects | COMPLETED | PHASE2 |
| NCT01384734 | HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections | COMPLETED | PHASE2 |
| NCT02105987 | A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen | COMPLETED | PHASE3 |
| NCT01536873 | Dolutegravir Expanded Access Study | COMPLETED | NA |
| NCT01641809 | Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine | COMPLETED | PHASE2 |
| NCT01199731 | Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection | TERMINATED | PHASE2 |
| NCT01328041 | A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. | COMPLETED | PHASE3 |
| NCT02951052 | Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02831764 | An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) | COMPLETED | PHASE3 |